Con: Kidney biopsy: An irreplaceable tool for patient management in nephrology

Nephrology Dialysis Transplantation

Volumn 30, Issue 4, 2015, Pages 528-531

  Glassock, Richard J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ACUTE KIDNEY FAILURE; ADVERSE OUTCOME; ARTICLE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; GOLD STANDARD; HUMAN; KIDNEY BIOPSY; KIDNEY FUNCTION; MEDICAL DECISION MAKING; MEMBRANOUS GLOMERULONEPHRITIS; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 84926677394     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv044     Document Type: Article

References (40)

1. Feldt-Rasmussen B, Brandi L, Olgaard K. In Memorium-Claus Brun. MD, Dr. Med., 1914-2014. Nephrol Dial Transplant 2014; 29: 2348-2349
2. Iverson P, Brun C. Aspiration biopsy of the kidney. Am J Med 1951; 11: 324-330
3. Muehrcke RC, Kark RM, Pirani CL. Technique of percutaneous renal biopsy in the prone position. J Urol 1955; 74: 267-277
4. D'Agati VD, Mengel M. The rise of renal pathology in nephrology: structure illuminates function. Am J Kidney Dis 2013; 61: 1016-1025
5. Dhuan N, Bellamy CO, Cattran DC et al. Utility of renal biopsy in the clinical management of renal disease. Kidney Int 2014; 85: 1039-1048
6. Mellors RC, Ortega LG. Analytical Pathology III. New observations on the pathogenesis of glomerulonephritis, lipid nephrosis, periarteritis nodosa and secondary amyloidosis in man. Am J Pathol 1956; 32: 455-499
7. Farquhar MG, Vernier RL, Good RA. The application of electron microscopy in pathology: study of renal biopsy tissues. Schweiz MedWochenschr 1957; 887: 501-510
8. Sethi S, Theis JD, Vrana JA et al. Laser microdissection and proteomic analysis of amyloidosis, cryoglobulinemic GN, fibrillary GN and immunotactoid glomerulopathy. Clin J Am Soc Nephrol 2013; 8: 915-921
9. Gadegbeku CA, Gipson DS, Holzman LBN et al. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate glomerular nephropathy by a multi-disciplinary approach. Kidney Int 2013; 83: 749-756
10. Chang A, Gibson IW, Cohen AH et al. A position paper on standardizing the nonneoplastic kidney biopsy report. Clin J Am Soc Nephrol 2012; 7: 1365-1368
11. Williams WW, Taheri D, Tolkoff-Rubin N et al. Clinical role of the renal transplant biopsy. Nat Rev Nephrol 2012; 8: 110-121
12. Stokes MB, D'Agati VD. Morphologic variants of focal segmental glomerulosclerosis and their significance. Adv Chronic Kidney Dis 2014; 21: 400-407
13. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupsu erythematosus revisited. Kidney Int 2004; 65: 521-530A
14. Roberts IS, Cook HT, Troyanov S et al.Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. Kidney Int 2009; 76: 546-556
15. Berden AE, Fedrrario F, Hagen EC et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 2010; 21: 1628-1636
16. Tervaert TW, Mooyaart AL, Amann K et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 2010; 21: 556-563
17. Stratta P, Canavese CX, Marengo M et al. Risk management of renal biopsy: 1387 cases over 30 years in a single center. Eur J Clin Invest 2007; 37: 954-963
18. Tondel C, Vikse BE, Bostad L et al. Safety and complications of percutaneous kidney biopsy in 715 children and 8753 adults in Norway 1988-2010. Clin J Am Soc Nephrol 2012; 7: 1591-1597
19. Korbet SM, Volpini KC, Whittier WL. Percutaneous renal biopsy of native kidneys: a single center experience of 1,055 biopsies. Am J Nephrol 2014; 39: 153-162
20. Jin B, Zeng C, Ge Y et al. The spectrum of biopsy-proven kidney diseases in elderly Chinese patients. Nephrol Dial Transplant 2014; 29: 2251-2259
21. Cohen AH, Nast CC, Adler SG et al. Clinical utility of kidney biopsies in the diagnosis andmanagement of renal disease. Am J Nephrol 1989; 9: 309-315
22. Alsuwaida A, Husain S, Alghonaim M et al. Strategy for second kidney biopsy in patients with lupus nephritis. Nephrol Dial Transplant 2012; 27: 1472-1478
23. Haas M, Sis B, Racusen LC et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial; lesions. Am J Transplant 2014; 14: 272-283
24. Lee JR, Muthukumar T, Dadhania D et al. Urinary cell mRNA profiles predictive of human kidney allograft status. Immunol Rev 2014; 258: 218-240
25. Glassock RJ. Understanding recurrent glomerulonephritis in renal transplants: 50 years of progress. Clin Transpl 2013; 273-276
26. Moldoveanu Z, Wyatt RJ, Lee JY et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 2007; 71: 1148-1154
27. Suzuki H, Fan R, Zhang Z et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 2009; 119: 1668-1677
28. Glassock RJ. Anti-phospholipase A2 receptor autoantibody guided diagnosis and treatment of membranous nephropathy: a new personalized medical approach. Clin J Am Soc Nephrol 2014; 9: 1341-1343
29. Spinale JM, Mariani LH, Kapoor S et al. A re-assessment of soluble urokinase-type plasminogen activator receptor in glomerular disease. Kidney Int 2015; 87: 564-574
30. Yadav P, Leung N, Sanders P et al. The use of immunoglobulin light chain assays in the diagnosis of paraprotein-related kidney disease. Kidney Int 2015; 87: 564-574
31. Szeto CC, Li PK. MicroRNAs in IgA nephropathy. Nat Rev Nephrol 2014; 10: 249-256
32. Jiang S, Wang Y, Liu Z. The application of urinary proteomics for the detection of biomarkers of kidney diseases. Adv ExpMed Biol 2015; 845: 151-165
33. Yanagawa H, Suzuki H, Suzuki Y et al. A panel of serum, biomarkers differentiates IgA nephropathy from other renal diseases. PLoS One 2014; 9: e98081
34. Astor B, Matsushita K, Gansevoort RT et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int 2011; 790: 1331-1340
35. Cattran DC, Reich HN, Beanlands HGJ et al. The impact of sex in primary glomerulonephritis. Nephrol Dial Transplant 2008; 23: 2247-2253
36. An Y, Xu F, Ge Y et al. Renal histologic changes and the outcome in patients with diabetic nephropathy. Nephrol Dial Transplant 2015; 30: 257-266
37. Bazzi C, Rizza V, Casellato D et al. Fractional excretion of IgG in idiopathic membranous nephropathy with nephrotic syndrome: a predictive marker of risk and drug responsiveness. BMC Nephrol 2014; 15: 74
38. Chung AC, Yu X, Lan HY. MicroRNA and nephropathy: emerging concepts. Int J Nephrol Renovasc Dis 2013; 6: 169-179
39. Vickers AJ, Pepe M. Does the Net Reclassification Improvement help us evaluate models and markers? Ann Intern Med 2014; 160: 136-137
40. Berthoux F, Suzuki H, Thibaudin L et al. Auto-antibodies targeting galactose deficient IgA1 associates with progression of IgA nephropathy. J Am Soc Nephrol 2012; 23: 1579-1587